Can Nattokinase Dissolve Plaque in the Arteries?

"Dissolve plaque in the arteries" is one of the most common promises attached to nattokinase — and one of the most misunderstood.

Nattokinase is a genuinely potent clot-dissolving enzyme, but a blood clot and an artery-wall plaque are not the same thing. In the largest placebo-controlled trial to date — 265 adults followed for a median of 3 years — nattokinase showed no measurable effect on atherosclerosis progression. This article separates what the enzyme actually does from what the label implies — for the full picture, start with our complete guide to nattokinase.

Table of Contents

• 1. What "Dissolving Plaque" Actually Means
• 2. How Nattokinase Works: A Clot Enzyme, Not a Plaque Solvent
• 3. What the Human Studies Actually Show
• 4. The Dose Problem: Why a Standard Capsule May Not Match the Trials
• 5. Can Arterial Plaque Be Reduced at All?
• 6. Safety, Bleeding Risk, and Who Should Avoid It
• BioAbsorb Nattokinase Enzyme: An Honest Look
• Frequently Asked Questions
• Conclusion

1. What "Dissolving Plaque" Actually Means

The phrase "dissolve plaque" assumes plaque is a single substance that can be melted away, but atherosclerotic plaque is a layered structure built into the artery wall itself. According to the Cleveland Clinic, plaque (atheroma) is a buildup of fat, cholesterol, calcium, and other substances that accumulates gradually over years and narrows the vessel.

A mature plaque has a cholesterol-rich core, a fibrous cap of smooth muscle and connective tissue, and, over time, hardened calcium deposits. That is a very different target from a blood clot, which is a fresh mesh of the protein fibrin. This distinction is the single most important thing to understand before evaluating any supplement claim: a clot forms in the bloodstream, while plaque is embedded in the wall. An enzyme that clears one does not automatically clear the other.

This matters clinically because the two events are linked at the moment of danger. When a plaque's thin cap ruptures, the body forms a fibrin clot at that site, and it is the clot — not the plaque alone — that can suddenly block the artery and trigger a heart attack or stroke. A fibrinolytic enzyme is theoretically relevant to that clotting step, which is a far narrower and more defensible role than "cleaning out" an artery. We look at that clotting role in depth in our guide to nattokinase and blood clots.

2. How Nattokinase Works: A Clot Enzyme, Not a Plaque Solvent

Nattokinase is a serine protease derived from natto, a fermented soybean food. Its defining action is fibrinolysis: it directly degrades fibrin and boosts the body's own clot-clearing pathways by raising tissue plasminogen activator (tPA), degrading PAI-1, and converting prourokinase to urokinase.

A 2018 review in Biomarker Insights details how nattokinase cleaves and inactivates PAI-1, the main brake on fibrinolysis, which amplifies the enzyme's clot-lysing effect. In practical terms, these mechanisms explain why nattokinase is studied mostly for clotting, circulation, and blood flow — not for stripping cholesterol out of an artery wall.

A 2025 critical review echoes this while adding a caution: nattokinase's oral stability and bioavailability remain open questions, and its anti-atherosclerotic effects in humans are far less established than its fibrinolytic activity in the lab. For a step-by-step look at how nattokinase's fibrinolytic action works, see our dedicated explainer.

3. What the Human Studies Actually Show

Three human studies dominate this conversation, and they disagree. A 2017 randomized trial of about 80 patients compared nattokinase at 6,000 FU/day against simvastatin 20 mg/day over 26 weeks and reported reductions in carotid intima-media thickness (IMT) and plaque size in both groups. The catch: it had no placebo arm, so natural variation cannot be ruled out.

A larger 2022 study of 1,062 participants taking 10,800 FU/day for 12 months reported significant reductions in carotid IMT and plaque size, with improvement rates of 66.5–95.4% — but a lower dose of 3,600 FU/day was ineffective, and the study was retrospective, meaning it cannot prove cause and effect.

Then there is the most rigorous test: the Nattokinase Atherothrombotic Prevention Study (NAPS). This double-blind, placebo-controlled RCT of 265 adults taking 2,000 FU/day for a median 3 years found no significant difference from placebo in atherosclerosis progression, arterial stiffness, blood pressure, or any lab measure. When the best-designed study is the one that finds nothing, honesty requires leading with that result.

4. The Dose Problem: Why a Standard Capsule May Not Match the Trials

Dose is where the evidence and the marketing diverge most sharply. The two studies that reported plaque changes used 6,000 FU and 10,800 FU per day — roughly 3 to 5 times the 2,000 FU in a typical single capsule.

The one trial that used a standard 2,000 FU daily dose found no atherosclerosis benefit at all. The 2022 study reinforced this pattern from the other direction: at 3,600 FU/day, nattokinase was reported as ineffective for suppressing atherosclerosis progression. Taken together, these results suggest that any anti-plaque signal, if real, may depend on doses well above what a once-daily capsule delivers — and even those higher-dose findings come from studies that could not prove causation. Our nattokinase dosage guide covers how the standard 2,000 FU dose is typically taken.

5. Can Arterial Plaque Be Reduced at All?

Yes — but "reduced" is not the same as "dissolved." Established plaque can shrink modestly and, more importantly, become more stable, but arteries do not return to a pristine state. The Cleveland Clinic explains that statins work mainly by lowering LDL cholesterol to slow new plaque formation and by strengthening the fibrous cap so plaque is less likely to rupture.

That reframes where nattokinase might plausibly help. Its fibrinolytic activity is relevant to clot formation on top of a plaque — a common trigger of heart attacks and strokes — rather than to clearing the plaque itself. That is a meaningful distinction, but it is not the same as the "artery-cleaning" claim, and no trial has shown that a standard nattokinase dose prevents those events in people.

6. Safety, Bleeding Risk, and Who Should Avoid It

Because nattokinase promotes fibrinolysis, its main safety concern is bleeding. A professional drug monograph notes that nattokinase can increase bleeding risk when combined with anticoagulant or antiplatelet drugs such as warfarin, aspirin, or clopidogrel, and advises avoiding it before and after surgery.

The same source advises caution in people with ischemic stroke history, peptic ulcer disease, or coagulation disorders, and notes that safety data in pregnancy and breastfeeding are lacking. Small, short-term trials generally reported no serious adverse effects, but that reassurance applies to low-risk users — not to anyone on blood thinners. Anyone taking cardiovascular medication or managing a diagnosed heart condition should treat nattokinase as a decision to make with a physician, not instead of one. For a fuller breakdown of nattokinase side effects and cautions, see our detailed safety guide.

BioAbsorb Nattokinase Enzyme: An Honest Look

If you have decided that a nattokinase supplement fits your situation — realistically, and ideally after a conversation with your doctor — quality and transparency matter more than bold claims. BioAbsorb Nattokinase Enzyme delivers 100 mg (2,000 FU of fibrinolytic activity) per capsule in a once-daily dose, using DRcaps delayed-release capsules that protect the enzyme from stomach acid without the phthalates or plasticizers found in some enteric coatings.

A few details are worth naming plainly. The formula is intentionally free of Vitamin K2, which matters for anyone mindful of K2 interactions with warfarin, and every batch is third-party tested for potency (at least 2,000 FU), heavy metals, and microbial contaminants. It is non-GMO, 100% vegetarian, and free of gluten, nuts, eggs, dairy, fish, and shellfish, and it is manufactured in a Canadian GMP-certified facility. What BioAbsorb does not claim is that this product dissolves arterial plaque — because, as the evidence above shows, the 2,000 FU dose has not demonstrated that in a controlled trial. It is a transparently made enzyme supplement, not a treatment for atherosclerosis.

Frequently Asked Questions

Does nattokinase dissolve existing arterial plaque?

There is no reliable evidence that it dissolves established plaque. Nattokinase breaks down fibrin in blood clots, while plaque is a fat-, cholesterol-, and calcium-based structure in the artery wall. The one placebo-controlled trial at 2,000 FU/day found no effect on atherosclerosis.

Why do some articles say it reduces plaque?

Two human studies did report reductions in carotid plaque size, but they used much higher doses — 6,000 FU and 10,800 FU per day. One lacked a placebo group and the other was retrospective, so neither can prove nattokinase caused the change.

Is nattokinase the same as a blood thinner?

Not exactly. It supports the body's clot-breakdown system rather than blocking clotting factors like prescription anticoagulants do. Even so, it can add to bleeding risk, so it should not be combined with blood thinners without medical supervision.

What dose was used in the studies?

Doses ranged widely: 2,000 FU/day in the null NAPS trial, 6,000 FU/day versus simvastatin in a 26-week study, and 10,800 FU/day in the 1,062-participant retrospective study. A standard capsule typically provides 2,000 FU, the dose that showed no atherosclerosis benefit.

Should I stop nattokinase before surgery?

Yes. Because of its effect on fibrinolysis, the standard guidance is to discontinue nattokinase well before surgery or dental procedures and to tell your surgical team you have been taking it. Restart only with a clinician's approval.

Can I get nattokinase from food instead?

Nattokinase comes from natto, a fermented soybean food, but the traditional food also contains Vitamin K2, which can interfere with warfarin. Supplements usually remove K2, whereas eating natto does not — a distinction worth noting for anyone on anticoagulants, per the same safety guidance.

Conclusion

The honest answer is that nattokinase is not proven to dissolve arterial plaque, and the best-designed trial — 265 adults over 3 years at 2,000 FU/day — found no benefit for atherosclerosis at all. It remains an interesting fibrinolytic enzyme with a role in clot biology, not an artery-cleaning treatment. If you and your doctor decide a quality-tested enzyme supplement fits your goals, you can review the BioAbsorb Nattokinase Enzyme and its third-party test results.

Research References

1. Nattokinase atherothrombotic prevention study: a randomized controlled trial. Clinical Hemorheology and Microcirculation, Vol. 78, Issue 4 (2021), pp. 339–353. Placebo-controlled RCT of 265 adults at 2,000 FU/day for a median 3 years; found a null effect on subclinical atherosclerosis progression, arterial stiffness, and blood pressure.
2. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, Vol. 9 (2022), article 964977. Retrospective study reporting reduced carotid IMT and plaque size at 10,800 FU/day, with 3,600 FU/day ineffective; cannot establish causation.
3. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia (Ren et al.). Zhonghua Yi Xue Za Zhi (National Medical Journal of China), Vol. 97, Issue 26 (2017), pp. 2038–2042. RCT comparing nattokinase 6,000 FU/day with simvastatin over 26 weeks; reported carotid IMT and plaque reductions, but had no placebo arm.
4. Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease (Weng et al.). International Journal of Molecular Sciences, Vol. 18, Issue 3 (2017), article 523. Mechanistic review describing direct fibrin degradation and enhancement of tPA and urokinase with PAI-1 breakdown.
5. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases (Chen et al.). Biomarker Insights, Vol. 13 (2018), pp. 1–8. Review detailing PAI-1 inactivation and enhanced fibrinolysis; notes limited human outcome data.
6. Insights on the therapeutic potential of fibrinolytic enzymes, emphasis on Nattokinase. Discover Applied Sciences (Springer Nature) (2025). Critical review covering nattokinase's cardiovascular effects alongside unresolved stability and bioavailability challenges.
7. Atherosclerosis — Symptoms, Causes & Treatment. Cleveland Clinic (2025). Describes arterial plaque as a buildup of fat, cholesterol, calcium, and other substances within the artery wall.
8. Can Statins Actually Reverse Plaque Buildup? Cleveland Clinic (2025). Explains that plaque management works through LDL reduction and fibrous-cap stabilization rather than dissolution.
9. Nattokinase — Uses, Benefits & Dosage. Drugs.com professional monograph (2026). Summarizes bleeding-risk interactions, perioperative cautions, and gaps in pregnancy safety data.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.